Pain during walking and ascending stairs before hyaluronic acid injection was common in patients with knee osteoarthritis: a qualitative study

Ömer ÖZKAN, Naila BABAYEVA, Şerife Şeyma TORGUTALP, Ömer Serkan KARA, Gürhan DÖNMEZ, Feza KORKUSUZ

Department of Sports Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Background/aim: Knee osteoarthritis (OA) is a common pathology characterized by degeneration of the articular cartilage. The aim of the research was to ask patients how they decided to make the injection, what treatments they received, their complaints prior to and after the injection and how they feel at the moment, and whether they are currently exercising or not. Thus, to demonstrate the patients' outcomes with their own expression.

Materials and methods: A total of 92 knee OA patients completed semi-structured interviews, which included six open-ended questions.

Results: A total of 92 patients (66 female, 26 male) aged between 36 and 95 years (mean 65.5±11.1) were included. Before the injection, the majority of the OA patients had pain complaints when walking (72.8%) and 'ascending stairs (70.7%). One to four years after intraarticular injection, 45.2% of patients felt a decrease in their complaints. The majority of patients did not consider diet and exercise as a treatment option. In addition, almost all patients declared that they decided on hyaluronic acid injection treatment with the physician’s recommendation.

Conclusion: Pain during walking and ascending stairs before hyaluronic acid injection was common in knee-OA patients. Overall the patients felt a decrease in the symptoms after injection. Patients did not consider diet and exercise as a treatment option despite the recommendation by a physician.

Key words: Knee, osteoarthritis, qualitative study, injection, hyaluronic acid

1. Introduction

Progressive joint pain, deformity and limitation of movement are common clinical findings of osteoarthritis (OA) that may decrease the quality of life and may lead to morbidity and mortality [1, 2]. The knee joint is the most common site of OA among the peripheral joints and is retained the second after the spine in the entire body [3, 4]. Progression of OA can lead to total arthroplasty of the knee joint [5]. The intraarticular injection of hyaluronic acid (HA), also called viscosupplementation, is a nonsurgical approach to the treatment of OA and has become an increasingly popular treatment method in recent years [6–8].

Several studies related to the knee OA have found that HA injection is an effective and safe treatment for improving the functional status and decreasing pain, along with causing less significant side effects [7–10]. According to a Cochrane review, HA injection has a therapeutic benefit for pain during weight-bearing over placebo at 5 to 13 weeks postinjection [11]. On the other hand, other metaanalysis showed no significant results involving pain relief and functional improvement after the use of HA [12].

To better understand patients’ perception and outcome of the knee function after the treatment, patient-reported measures such as questionnaires are used widely in clinical and research practice [13]. More recent metaanalysis on this matter by Zhang et al. [14] found that platelet-rich plasma (PRP) injections were more effective in reducing pain than HA injections in knee OA patients at 6 and 12 months of follow-up assessed by the Western Ontario and McMaster Universities arthritis index (WOMAC) pain score questionnaire, whereas the visual analogue scales (VAS) questionnaire showed no significant difference at 3 and 6 months. On the other hand, in a double-blind randomized controlled trial of Cole et al., WOMAC measures did not show a significant difference between PRP and HA groups [15].

Different from this quantitative studies, the qualitative study attempts to find the meaning of the case through descriptions, experiences, and views of the participants.
Based on this, the researcher seeks to analyze the subjects’ history regarding topic of interest in and deduce in terms of meaningfulness and importance [17]. This form of research allows participants to express their views on their own terms. Mays and Pope [18] pointed out that this type of interview is a flexible and powerful tool and can open up new areas for research. Thus, the qualitative method was deemed as a useful tool in the measurements of the outcomes after HA injection, while it has a potential to develop the uncovered field, due to the lack of qualitative research in this area.

To our knowledge, patient-centered qualitative evaluation of the success of HA knee injection is based on very limited data. The aim of the research was, therefore, to evaluate patients’ perceptions, outcomes, and sports activity participation within 1–4 years after intraarticular HA injection, as a treatment option for knee OA.

2. Patients and method

2.1. Design
This study was designed based on the principles and methods of constructivist grounded theory [19]. Researchers’ goal was to obtain as much information as possible from the patients’ own words, to understand beliefs and actions from their perspectives and locate patients’ meanings within larger social structures and discussions in explorative qualitative research designs [20]. Data were obtained anonymously to ensure confidentiality.

2.2. Sampling and data collection
In this Turkish population-based qualitative designed study, 92 patients aged 36–95 years (mean 65.5±11.1), completed semistructured interviews. Included patients were individuals ≥35 years presenting with knee pain and (KL) grade 1–3 primary knee OA diagnosed according to American College of Rheumatology (ACR) classification Criteria. Thirty-one patients (34%) had KL grade 1 OA, 32 (35%) grade 2, and 29 (31%) grade 3. KL grade was determined by a physician experienced in Kellgren–Lawrence (KL) radiographic classification of knee osteoarthritis. Patients were free of any hearing or speech impairment. Other inclusion criteria were: pain >3 months, mean pain severity ≥2 on the numeric rating scale (NRS), (K&L) grade I to III in medial and/or lateral compartment as well. Patients with injuries of the knee, along with psychiatric disorders and dementia were excluded.

HA injections to participants were carried out every week for 3 weeks. A semistructured interview with six open-ended questions (Table 1) was developed by the research team, which consisted of experienced clinicians, to explore personal experiences and perspectives of patients after HA injections. They were conducted with patients within 1–4 years, 1st year as the earliest and 4th year as the latest period, after intraarticular HA injections. Interviews were conducted during routine outpatient clinic visits of patients, and then written down by two interviewers. Each interview with patients was audiotaped and transcribed verbatim with the average length of the interviews about 50 min. In the literature, semistructured interview refers to collect data by analyzing patient’s speech and its content [18].

2.3. Analysis
Open coding, axial coding and developing a core category that clarified the central matter of the data was used for data analysis [19–21]. All written answers were scanned and qualitative data analysis was conducted with each transcript individually read line by line by two researchers. Subsequent steps of the analysis consisted of identification of the relevant texts, fragmentation of the text in parts of meaning and developing code from the obtained data. Qualitative responses were coded and converted into quantified data by this method. These results were afterwards discussed with the whole research team regarding definitions and application of the codes to ensure validity. To enhance the trustworthiness of the data, an audit trail documenting the processes of data reduction and analysis was maintained.

3. Results
A total of 92 patients (66 female, 26 male) aged between 36 and 95 years (mean 65.5±11.1) were included. When patients were asked about their complaints prior to injection, the majority of them responded that they had complaints about the pain during walking (72.8%) and ascending stairs (70.7%). Responses of other patients were functional limitations (41.3%), waking up with pain at night (18.5%), unable to sit on the knees (16.3%),

| Table 1. Six open-ended questions. |
|-----------------|-----------------|-----------------|
| 1. What was your complaint prior to injection? |
| 2. Which treatments were applied prior to the injection? |
| 3. How did you decide to make an injection? |
| 4. What did you feel during first 3 days after injection? |
| 5. How do you feel yourself right now? |
| 6. Did you return to exercise? |
crepitations (14.1%), knee locking (12%) and sensation of ‘‘giving-way’’ (3.3%). A small minority of patients gave as an answer pain in cold weather and while standing, burning sensation, feeling of knee deformation and feeling like a sharp piece of glass is cutting into the knee (Table 2).

In response to the second question, patients reported that they had oral and/or topical NSAIDs (48.1%), physical therapy modalities (40.5%), injection (36.7%), exercises (15.2%), oral chondroprotective agents (11.4%) and other treatments like cold bandage, cold pack and alternative medicine (8.9%) (Table 2).

When the subjects were asked how they decided to receive an intraarticular injection, it was shown that 90.2% of patients decided to have an injection with the physician’s recommendation, 15.2% of patients decided under the influence of their friends and others and 3.3% of patients decided because of their constant pain. According to the patients, other reasons for intraarticular injection were individual explorations such as a search on the Internet and considering the injection as the last option before the operation (6.5%) (Table 2).

56% of those surveyed reported that after intraarticular injection, they felt no difference, where 25% of them felt themselves more comfortable. Only 10.9% of the respondents declared that their pain increased after the HA injection, and 8.6% do not remember how they felt during first 3 days after intraarticular injection (Table 2).

In order to obtain more information regarding side effects after HA injections, the fourth question was therefore extended. The majority of respondents (72%) felt none of the following symptoms: joint warmth, pain, fever or local erythema (Table 2).

One to four years after the intraarticular injection, 45.2% of patients felt a decrease in their complaints, 19.6% of patients had no complaints at all, 17.4% of patients did not feel any changes, whereas 17.4% of patients are currently observed relapse after initial symptoms’ reduction, and the remaining 1.1% of patients whose complaints have increased (Table 2).

After intraarticular injection, 40.9% of patients resumed walking, 10.2% of patients resumed to home-based exercises and 9.1% of patients resumed to swimming on a weekly basis, whereas 47.7% of patients did not return any type of exercise.

4. Discussion
The most common form of arthritis, along with the fastest growing reason of disability in the world, is OA [22]. About 18% of women and 9.6% of men over 60 years worldwide experience a symptomatic OA, and 25% of them do not perform everyday physical activities [23]. Intraarticular HA injections have become an increasingly popular treatment method in OA, in recent years due to their effectiveness and safety issues [6–8]. To the best of our knowledge, this is the first study with a qualitative evaluation of patients’ perception who previously underwent HA injection in the knee joint.

The values of diseases are reflected in the personal experience of people describing their conditions [24]. According to The American College of Rheumatology, there are some key symptoms for osteoarthritis, including morning stiffness lasting 30 min, crepitus on motion, bony tenderness and bony enlargement [25]. Patients’ responses in this study are in line with these criteria. In our study, when the subjects were asked about their main complaints, 41.3% of them answered that they have functional limitations and 14.1% have crepitations, along with 17.4% of other complaints including bony enlargement. The majority of the respondents declared that they experience pain during walking (72.8%) and ascending the stairs (70.7%).

Treatment options for OA are individualized for the patients’ needs and preferences in order to provide high-quality care for relieving these symptoms and improve quality of life [26]. According to the guideline of OA Research Society International (OARSI), that was published in 2014 [27], land- and water-based exercises, strength training, and weight management are the core treatments applicable to all individuals. Along with the aforementioned, additional pharmacological interventions can be advised, structured on the characteristics of the individual patient. When our patients were asked about treatments that were applied prior to injection, 48.1% took (NSAIDs) and 40.5% proceeded to physical therapy. In a metaanalysis of Bannuru et al. [28], where the data regarding the efficacy of HA in comparison with nonsteroidal antiinflammatory drugs (NSAIDs) for knee OA was obtained, declared that there was no significant difference between HA and NSAIDs in continuous follow-up at 4 and 12 weeks. However, given the more favorable safety in favor of HA over NSAIDs, the authors stated that HA might be an alternative to NSAIDs for knee OA, especially for elderly patients with a high risk of systemic side effects. More recent pieces of evidence suggest that various forms of exercise have positive effects on pain and joint function for OA patients [29,30]. However, only 9.4% of those surveyed reported that exercise program was recommended as a treatment in our study. These findings are consistent with previous reports on low-rate recommendation of exercise, noncompliance to exercise therapy and lifestyle counseling, and warrant further investigation to increase this low level of adherence [31,32]. The most appropriate knee OA management, including exercise therapy, should be designed according to a patient-centered approach.

When patients are facing serious illnesses, which can cause changes in body image and lifestyle activity, it
Table 2. Answers of the participants to open-ended questions.

| N = 92 | N* | %  |
|--------|----|----|
| 1.     |     |    |
| What was your complaint prior to injection? |     |    |
| Pain during walking | 67  | 72.8 |
| Pain during ascending the stairs/hill | 65  | 70.7 |
| Functional limitations | 38  | 41.3 |
| Waking up with pain at the night | 17  | 18.5 |
| Unable to sit on the knees | 15  | 16.3 |
| Crepitations | 13  | 14.1 |
| Knee locking | 11  | 12   |
| Sensation of "giving away" | 3   | 3.3  |
| Other | 16  | 17.4 |
| 2.     |     |    |
| Which treatments were applied prior to injection? |     |    |
| Oral/topical NSAIDs | 38  | 48.1 |
| Physical therapy | 32  | 40.5 |
| Injection | 29  | 36.7 |
| Exercise | 12  | 15.2 |
| Oral chondroprotective agents | 9   | 11.4 |
| Other | 7   | 8.9  |
| 3.     |     |    |
| How did you decide to make an injection? |     |    |
| Physician's recommendation | 83  | 90.2 |
| Friend/community | 14  | 15.2 |
| Complains | 3   | 3.3  |
| Other | 6   | 6.5  |
| 4.     |     |    |
| What did you feel during first 3 days after injection? |     |    |
| Did not feel any difference | 52  | 56.5 |
| Felt more comfortable | 23  | 25   |
| Pain increased | 10  | 10.9 |
| Do not remember | 8   | 8.6  |
| 5.     |     |    |
| How do you feel yourself right now? |     |    |
| Complaints decreased | 42  | 45.6 |
| Do not have any complaints | 18  | 19.5 |
| Complaints remained unchanged | 16  | 17.4 |
| At the beginning complaints decreased/gone, but now recrudescence in complaints | 16  | 17.4 |
| Complaints increased | 1   | 1.1  |
| 6.     |     |    |
| Did you return to the exercise? |     |    |
| None | 42  | 47.7 |
| Walking | 36  | 40.9 |
| Home exercises | 9   | 10.2 |
| Swimming | 8   | 9.1  |
| Running | 3   | 3.4  |

*Valid response category percentages > 100% because each response could contain more than one coded unit.
is important to understand what influenced the patients regarding the decision-making process in treatment options. When the subjects were asked what influenced their decision to undergo HA injection of the knee joint, 90.2% said that the decision to choose a treatment option was proposed on the recommendation of the doctor. This result is in conformity with previous studies, showing the role of physician on decision making process [33]. It has been reported that HA is most frequently prescribed by physicians to patients with early-stage (82%) or mid-stage (82.8%) OA [34]. To our knowledge, this is the first qualitative designed paper addressing the role of clinician’s in choosing the use of HA for the treatment of knee OA. It is important to note that physicians have a potential influence regarding treatment recommendations that influence the choice of patients.

The recommendations of the European League against Rheumatism (EULAR) show that there is evidence to support the effectiveness of HA in accordance with the level 1B indications for both pain reduction and joint functional improvement of the knee joint [35]. However, the expected effect can be obtained within a few months, rather than within a few weeks, as with the use of a steroid. Patients’ responses regarding their well-being during first 3 days after intra-articular injection, 56.5% of those surveyed reported no difference, where 25% of them felt themselves more comfortable. Only 10.9% of the respondents declared that their pain increased after the HA injection and 8.6% don’t remember how they felt during first 3 days after intraarticular injection.

In order to get more information regarding side effects after HA injections, the aforementioned question was therefore extended and the 71% of respondents felt none of the following symptoms: joint warmth, pain, fever or local erythema. These results were similar to a systematic review and metaanalysis of Millers et al.[36], where the safety and efficacy of US-approved HA knee injections were randomized with saline controls, found no statistical difference regarding serious adverse effects between these two groups in patients with knee OA. Some adverse effects such as increased rate of flare [37], granulomatous inflammation [38] and a few local infections (like septic arthritis) have also been reported. A recent systematic review found no difference in the side effect rate between single injections of HA and placebo [39]. In our study, 21.7% of patients felt pain, fever or erythema, and none of our patients described any serious adverse effects like septic arthritis. The Cochrane review of 2014 showed that viscosupplementation for the knee OA provides pain relief and improved physical function with a low risk of harm [40].

Many researchers have studied the efficacy of HA injection in the treatment of the knee OA in long-term. According to the recent analysis of US-approved HA injections showed a better treatment effect compared to preinjection values from 4 weeks to 26 weeks for pain and knee function, in comparison with placebo [36]. In the study of Miltnr et al.[41], where patients underwent HA injection, showed improvement at VAS and maximum peak-torque. In 2010, Chevalier et al.[42], stated that a single 6-mL intraarticular injection of Hylan G-F 20 was safe and effective in providing statistically significant and clinically relevant pain relief over 26 weeks, with a modest difference versus placebo. Our study is in line to these studies, where we found that 45.6% of patients felt the decrease in their complaints, 19.5% of patients currently do not have any complaints, and 17.4% of patients had at the beginning complaints decreased and even gone, but now recrudescence in complaints. DeCaria et al.[43] reported no difference in gait velocity compared with placebo, but they found that patients treated with HA had improvements in WOMAC scores for pain, stiffness, and physical function.

Our study has several limitations including, prominently, the fact that the respondents were patients of the same hospital, and hence the results cannot be applied to the general population. Therefore, future studies with a larger sample with knee OA should be recruited. Secondly, there were difficulties in translating the patients’ interviews from Turkish to English in the concept of research results, even though the translation was performed by a professional translator who did not interview the subjects in this study. In consequence, the researchers repeatedly discussed the accuracy of the translation, so that the basic concepts were not lost in the translation. Therefore, future studies are needed to overcome these issues.

In conclusion, we would like to mention that despite all the limitations, this research, to our best knowledge is the first qualitative study regarding outcomes before and after HA injection. Our study identified main complaints of the patients before injection, which were following, the pain when walking and ascending stairs. Most of the patients underwent treatments prior to HA injections; however, many patients didn’t consider diet and exercises as a treatment option. Along with the aforementioned, our findings showed that choosing HA as a treatment option was proposed on the recommendation of the doctor. Therefore, physicians should improve their relationship with the patient by providing adapted and formalized information to patients regarding the efficacy of treatment strategies, adapting more approved guidelines and therapeutic approaches, which are the main factors of symptoms’ improvement in OA.

Acknowledgment/disclaimers/conflict of interest
Each of the authors has contributed to, read and approved this manuscript. The authors declare that no conflict of interest and do not have any financial disclosures.
Informed consent
All the participants gave written informed consent prior to the study and this study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Hacettepe University (Decision number: KA-180014).

References

1. Rubin BR. Management of osteoarthritic knee pain. The Journal of the American Osteopathic Association 2005; 105 (9 Suppl. 4): S23-S28.

2. Hawker GA, Croxford R, Bierman AS, Harvey PJ, Ravi B et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One 2014; 9 (3): e91286. doi: 10.1371/journal.pone.0091286

3. Liu Q, Niu J, Huang J, Ke Y, Tang X et al. Knee osteoarthritis and all-cause mortality: the wuchuan osteoarthritis study. Osteoarthritis Cartilage 2015; 23 (7): 1154-1157. doi: 10.1016/j.joca.2015.03.021

4. Michael JW, Schluter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. Deutsches Arzteblatt International 2010; 107 (9): 152-162. doi: 10.3238/arztebl.2010.0152

5. Belcher C, Yakub R, Fawthrop F, Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Annals of the Rheumatic Diseases 1997; 56 (5): 299-307. doi: 10.1136/ard.56.5.299

6. Pelletier JP, Martel-Pelletier J. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. Journal of Rheumatology Supplement 1993; 39: 19-24.

7. Maheu E, Ayral X, Dougados M. Hyaluronan in knee osteoarthrosis: a review of the clinical trials with hyalgun*. European Journal of Rheumatology and Inflammation 1995; 15 (1): 17-24.

8. Campbell KA, Erickson BJ, Saltzman BM, Mascalzhenas R, Bach Jr BR et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthrosis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy 2015; 31 (10): 2036-2045. doi: 10.1016/j.arthro.2015.03.030

9. Strand V, McIntyre LF, Beach WR, Miller LE, Block JE. Safety and efficacy of us-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. Journal of Pain Research 2015; 8: 217-228. doi: 10.2147/jpr.S83076

10. Dahlgberg L, Lohmander LS, Ryd L. Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one-year double-blind, placebo-controlled study. Arthritis & Rheumatology 1994; 37 (4): 521-528. doi: 10.1002/art.1780370412

11. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2006; 19 (2): Cd005321. doi: 10.1002/14651858.CD005321.pub2

12. Jevsevar D, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for osteoarthrosis of the knee: a systematic review of the evidence. The Journal of Bone and Joint Surgery 2015; 97 (24): 2047-2060. doi: 10.2106/jbjs.N.00743

13. Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee function: International knee documentation committee (ikdc) subjective knee evaluation form, knee injury and osteoarthritis outcome score (koos), knee injury and osteoarthritis outcome score physical function short form (koos-ps), knee outcome survey activities of daily living scale (kos-adl), lsholm knee scoring scale, oxford knee score (oks), western ontario and mcmaster universities osteoarthritis index (womac), activity rating scale (ars), and tegner activity score (tas). Arthritis Care & Research 2011; 63 (S1): S208-S228. doi: 10.1002/acr.20632

14. Zhang HF, Wang CG, Li H, Huang YT, Li ZJ. Intra-articular platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis. Drug Design, Development and Therapy 2018; 12: 445-453. doi: 10.2147/dddt.S156724

15. Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Hyaluronic acid versus platelet-rich plasma: A prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. American Journal of Sports Medicine 2017; 45 (2): 339-346. doi: 10.1177/0363546516665809

16. Al-Busaidi ZQ. Qualitative research and its uses in health care. Sultan Qaboos University Medical Journal 2008; 8 (1): 11-19.

17. Etherington K. Becoming a reflexive researcher. 1st ed. London, England: SAGE Publications Ltd; 2014.

18. Mays N, Pope C. Rigour and qualitative research: a review of the design and procedures for developing grounded theory. Quality Assurance of Qualitative Research: A Review of the Design and Procedures for Developing Grounded Theory. 3rd ed. Thousand Oaks, CA, USA: SAGE Publications, Inc; 2008. doi: 10.4135/9781452230153

19. Charrez K. Constructing grounded theory. 2nd ed. London, England: SAGE Publications Ltd; 2014.

20. Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 3rd ed. Thousand Oaks, CA, USA: SAGE Publications, Inc; 2008. doi: 10.4135/9781452230153

21. Reynolds J, Kizito J, Ezumah N, Mangesho P, Allen E et al. Quality assurance of qualitative research: a review of the discourse. Health Research Policy and Systems 2011; 9 (1): 43. doi: 10.1186/1478-4505-9-43
22. Ahmad HS, Farrag SE, Okasha AE, Kadry AO, Ata TB et al. Clinical outcomes are associated with changes in ultrasonographic structural appearance after platelet-rich plasma treatment for knee osteoarthritis. International Journal of Rheumatic Diseases 2018; 21 (5): 960-966. doi: 10.1111/1756-185x.13315

23. Thomas S, Browne H, Mobasher A, Rayman MP. What is the evidence for a role for diet and nutrition in osteoarthritis? Rheumatology 2018; 57 (Suppl. 4): iv61-iv74. doi: 10.1093/rheumatology/key011

24. MacKay C, Sale J, Badley EM, Jaglal SB, Davis AM. Qualitative study exploring the meaning of knee symptoms to adults ages 35-65 years. Arthritis Care & Research 2016; 68 (3): 341-347. doi: 10.1002/acr.22664

25. Altman R, Asch E, Bloch D, Bole G, Borenstein D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American rheumatism association. Arthritis & Rheumatology 1986; 29 (8): 1039-1049. doi: 10.1002/art.1780290816

26. Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Chris-tensen P et al. Eular recommendations for the non-pharmaco logical core management of hip and knee osteoarthritis. An- nals of the Rheumatic Diseases 2013; 72 (7): 1125-1135. doi: 10.1136/annrheumdis-2012-202745

27. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Beren baum F et al. Oarsi guidelines for the non-surgical manage ment of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363-388. doi: 10.1016/j.joca.2014.01.003

28. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with nsais for knee osteoarthritis: a systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 2014; 43 (5): 593-599. doi: 10.1016/j.semarthrit.2013.10.002

29. Skou ST, Pedersen BK, Abbott JH, Patterson B, Barton C. Physical activity and exercise therapy benefit more than just symptoms and impairments in people with hip and knee osteoarthritis. Journal of Orthopaedic & Sports Physical Therapy 2018; 48 (6): 439-447. doi: 10.2519/jospt.2018.7877

30. Brosseau L, Pelland L, Wells G, Macleay L, Lamothe C et al. Efficacy of aerobic exercises for osteoarthritis (part ii): a meta-analysis. Physical Therapy Reviews 2004; 9 (3): 125-145. doi: 10.1179/108331904225005061

31. Khoja SS, Almeida GJ, Freburger JK. Recommendation rates for physical therapy, lifestyle counseling, and pain medications for managing knee osteoarthritis in ambulatory care settings: a cross-sectional analysis of the national ambulatory care survey (2007–2015). Arthritis Care & Research 2020; 72 (2): 184-192. doi: 10.1002/acr.24064

32. Campbell R, Evans M, Tucker M, Quilty B, Dieppe P et al. Why don’t patients do their exercises? Understanding non-compliance with physiotherapy in patients with osteoarthritis of the knee. Journal of Epidemiology and Community Health 2001; 55 (2): 132-138. doi: 10.1136/jech.55.2.132

33. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Archives of Internal Medicine 1996; 156 (13): 1414-1420. doi: 10.1001/archinte.1996.00440120070006

34. Rosen J, Avram V, Fierlinger A, Niazi F, Sancheti P et al. Clinicians’ perspectives on the use of intra-articular hyaluronic acid as a treatment for knee osteoarthritis: a North American, multidisciplinary survey. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2016; 9: 21-27. doi: 10.4137/CMAMD.S34496

35. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW et al. Eular recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a task force of the standing committee for international clinical studies including therapeutic trials (escist). Annals of the Rheumatic Diseases 2003; 62 (12): 1145-1155. doi: 10.1136/ard.2003.011742

36. Miller LE, Block JE. Us-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2013; 6: 57-63. doi: 10.4137/CMAMD.S12743

37. Rutjes AW, Jüni P, Da Costa BR, Trelle S, Nüesch E et al. Visco-supplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Annals of Internal Medicine 2012; 157 (3): 180-191. doi: 10.7326/0003-4819-157-3-201208070-00473

38. Chen A, Desai P, Adler E, Dicesare P. Granulomatous inflam mation after hylan g-f 20 viscosupplementation of the knee - a report of six cases. The Journal of Bone and Joint Surgery 2002; 84-A (7): 1142-1147. doi: 10.2106/00004623-200312000-00041

39. Concoff A, Sancheti P, Niazi F, Shaw P, Rosen J. The efficacy of multiple versus single hyaluronic acid injections: a systematic review and meta-analysis. BMC Musculoskeletal Disorders 2017; 18 (1): 542. doi: 10.1186/s12891-017-1897-2

40. Evniew N, Simonovovic N, Karlsson J. Cochrane in CORR*: viscosupplementation for the treatment of osteoarthritis of the knee. Clinical Orthopaedics and Related Research 2014; 472 (7): 2028-2034. doi: 10.1007/s11999-013-3378-8

41. Miltner O, Schneider U, Siebert CH, Niedhart C, Niethard FU. Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis—a prospective clinical trial. Osteoarthritis Cartilage 2002; 10 (9): 680-686. doi: 10.1053/joca.2002.0815

42. Chevalier X, Jerosch J, Goupille P, Van Dijk N, Luyten FP et al. Single, intra-articular treatment with 6 ml hylan g-f 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Annals of the Rheumatic Diseases 2010; 69 (1): 113-119. doi: 10.1136/ard.2008.094623

43. DeCaria JE, Montero-Odasso M, Wolfe D, Chesworth BM, Pe trella RJ. The effect of intra-articular hyaluronic acid treatment on gait velocity in older knee osteoarthritis patients: a random ized, controlled study. Archives of Gerontology and Geriatrics 2012; 55 (2): 310-315. doi: 10.1016/j.archger.2011.11.007